Oragenics Inc (OGEN) shareholders
OGENNYSEPharmaceutical PreparationsFiscal year ends December 31
$0.20−0.15 (-42.59%)
Close on Nov 13, 2026Market cap $906.90KP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
1.5%
0M of 5M shares
Institutional holders
17
2 new, 5 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
0 buys · 2 sales
Net sold $395
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Sabby Management, LLC Joint filing with Hal Mintz (9.90%), Sabby Volatility Warrant Master Fund, Ltd. (9.90%) | 412,654 | 9.90% | 13G (passive) | Dec 31, 2025 |
| Five Narrow Lane LP | 82,210 | 9.99% | 13G (passive) | Jul 2, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of OGEN | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Geode Capital Management, LLC | 23,685 | 0.52% | $13.75K | −41,387 | 0.00% |
| 25 LLC | 23,160 | 0.51% | $13.45K | New | 0.00% |
| Jane Street Group, LLC | 12,771 | 0.28% | $7.41K | New | 0.00% |
| Tower Research Capital LLC (TRC) | 4,548 | 0.10% | $2.64K | – | 0.00% |
| St. Johns Investment Management Company, LLC | 1,924 | 0.04% | $1.12K | +1,724 | 0.00% |
| BlackRock, Inc. | 703 | 0.02% | $408 | – | 0.00% |
| UBS Group AG | 642 | 0.01% | $373 | −4,563 | 0.00% |
| Harbour Investments, Inc. | 34 | 0.00% | $20 | – | 0.00% |
| Wells Fargo & Company/Mn | 34 | 0.00% | $20 | – | 0.00% |
| SBI Securities Co., Ltd. | 23 | 0.00% | $13 | +12 | 0.00% |
| Adkins Seale Capital Management LLC | 3 | 0.00% | $2 | – | 0.00% |
| Royal Bank of Canada | 2 | 0.00% | $0 | +1 | 0.00% |
| Bogart Wealth, LLC | 1 | 0.00% | $1 | – | 0.00% |
| Strategic Wealth Partners, Ltd. | 1 | 0.00% | $1 | – | 0.00% |
| Farther Finance Advisors, LLC | 1 | 0.00% | $1 | – | 0.00% |
| Keating Financial Advisory Services, Inc. | 1 | 0.00% | $1 | – | 0.00% |
| Johnson Financial Group, Inc. | 1 | 0.00% | $1 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 17 | 0M | 1.5% | 2 / 3 | 2 / 5 | 0M | 0M |
| Q1 2026 | 20 | 0M | 4.2% | 11 / 2 | 1 / 9 | 0M | 0M |
| Q4 2025 | 19 | 0M | 4.8% | 5 / 5 | 0 / 2 | 0M | 0M |
| Q3 2025 | 16 | 0M | 2.7% | 4 / 1 | 5 / 5 | 0M | 0M |
| Q2 2025 | 18 | 0M | 2.3% | 18 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
1 funds held OGEN in Q2 2026, 0% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of OGEN | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 63,379 | 1.40% | $38.40K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| John Spencer | Chief Financial Officer | 53 | 0.00% | Jul 7, 2026 |
| Janet Huffman | CEO and CFO | 15,000 | 0.33% | Dec 15, 2025 |
| Fred Telling | Director | 948 | 0.02% | Jan 22, 2026 |
| Charles L. Pope | Director | 25,471 | 0.56% | Dec 15, 2025 |
| Natasha Giordano | Director | – | – | Dec 15, 2025 |
| John P. Gandolfo | Director | – | – | Dec 15, 2025 |
| Alan W. Dunton | Director | 25,623 | 0.57% | Dec 15, 2025 |
| Robert C. Koski | Director | 51,307 | 1.14% | Dec 15, 2025 |
| Odyssey Health, Inc. | 10% owner | 0 | – | Jun 18, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Fred Telling Director | Dec 12, 2025 | Sale | −210 | $0.94 | $197 | 948 |
| Fred Telling Director | Dec 12, 2025 | Sale | −210 | $0.94 | $197 | 34,538 |
| Odyssey Health, Inc. 10% owner | Jun 18, 2025 | Sale | −5,044 | $4.26 | $21.49K | 0 |
| Odyssey Health, Inc. 10% owner | Jun 17, 2025 | Sale | −2,000 | $4.46 | $8.92K | 5,044 |
| Odyssey Health, Inc. 10% owner | Jun 16, 2025 | Sale | −5,000 | $4.45 | $22.25K | 7,044 |
| Odyssey Health, Inc. 10% owner | Jun 13, 2025 | Sale | −5,000 | $4.27 | $21.35K | 12,044 |
| Robert C. Koski Director | Dec 11, 2024 | Conversion | +5,000 | – | – | 23,367 |
| Fred Telling Director | Dec 6, 2024 | Sale | −3,597 | $0.36 | $1.29K | 34,748 |
| Alan W. Dunton Director | Dec 6, 2024 | Sale | −66 | $0.36 | $24 | 25,623 |
| Fred Telling Director | Nov 30, 2023 | Sale | −3,500 | $3.57 | $12.50K | 38,345 |
| Robert C. Koski Director | Aug 8, 2023 | Award | +25,000 | – | – | 27,940 |
| Janet Huffman CFO, Secretary and Treasurer | Aug 8, 2023 | Award | +15,000 | – | – | 15,000 |
| Charles L. Pope Director | Aug 8, 2023 | Award | +25,000 | – | – | 25,471 |
| Alan W. Dunton Director | Aug 8, 2023 | Award | +25,000 | – | – | 25,689 |
| Robert C. Koski Director | Aug 8, 2023 | Award | +25,000 | – | – | 25,689 |
| Fred Telling Director | Aug 8, 2023 | Award | +25,000 | – | – | 41,845 |
| Kimberly M. Murphy CEO and President, Director | Aug 8, 2023 | Award | +25,000 | – | – | 25,000 |
| Robert C. Koski Director | Dec 30, 2022 | Sale | −42,357 | $0.11 | $4.66K | 1,102,295 |
| Robert C. Koski Director | Dec 29, 2022 | Sale | −36,648 | $0.11 | $4.03K | 176,191 |
| Robert C. Koski Director | Dec 15, 2022 | Sale | −140,497 | $0.18 | $25.29K | 1,144,652 |
| Robert C. Koski Director | Dec 14, 2022 | Sale | −25,000 | $0.18 | $4.50K | 1,285,149 |
| Robert C. Koski Director | Dec 14, 2022 | Sale | −4,503 | $0.18 | $811 | 1,310,149 |
| Robert C. Koski Director | Dec 9, 2022 | Sale | −48,795 | $0.20 | $9.76K | 1,314,652 |
| Robert C. Koski Director | Dec 8, 2022 | Sale | −13,036 | $0.20 | $2.61K | 1,363,447 |
| Robert C. Koski Director | Nov 30, 2022 | Sale | −200,000 | $0.19 | $38.00K | 1,376,483 |
| Robert C. Koski Director | Nov 29, 2022 | Sale | −200,000 | $0.19 | $38.00K | 1,576,483 |
| Fred Telling Director | Jun 17, 2022 | Buy | +10,084 | $0.29 | $2.92K | 1,010,000 |
| Fred Telling Director | May 24, 2022 | Buy | +78,673 | $0.29 | $22.82K | 999,916 |
| Fred Telling Director | May 23, 2022 | Buy | +3,500 | $0.29 | $1.02K | 921,243 |
| Fred Telling Director | May 20, 2022 | Buy | +65,718 | $0.28 | $18.40K | 917,743 |
| Fred Telling Director | May 19, 2022 | Buy | +56,806 | $0.28 | $15.91K | 852,025 |
| Fred Telling Director | May 18, 2022 | Buy | +15,303 | $0.26 | $3.98K | 795,219 |
| Fred Telling Director | Mar 31, 2022 | Buy | +59,053 | $0.35 | $20.67K | 779,916 |
| Fred Telling Director | Mar 30, 2022 | Buy | +124,785 | $0.36 | $44.92K | 720,863 |
| Michael O'Keefe Sullivan Interim PEO, CFO | Mar 29, 2022 | Buy | +20,000 | $0.35 | $7.00K | 34,255 |
| Robert C. Koski Director | Dec 31, 2021 | Buy | +799,100 | $0.47 | $375.58K | 1,776,483 |
| Robert C. Koski Director | Dec 30, 2021 | Buy | +200,900 | $0.45 | $90.41K | 977,383 |
| Fred Telling Director | Jun 29, 2021 | Option exercise | +156,540 | $0.48 | $75.14K | 596,078 |
| Joseph Hernandez 10% owner | Jan 14, 2021 | Sale | −870,854 | $0.98 | $853.44K | 0 |
| Joseph Hernandez 10% owner | Jan 13, 2021 | Sale | −257,510 | $0.80 | $206.01K | 870,854 |
| Joseph Hernandez 10% owner | Jan 12, 2021 | Sale | −629,707 | $0.73 | $459.69K | 1,128,364 |
| Joseph Hernandez 10% owner | Jan 11, 2021 | Sale | −441,929 | $0.77 | $340.29K | 1,758,071 |
| Joseph Hernandez 10% owner | Jan 7, 2021 | Sale | −323,997 | $0.84 | $272.16K | 2,200,000 |
| Joseph Hernandez 10% owner | Jan 6, 2021 | Sale | −1,000,000 | $0.60 | $600.00K | 2,523,997 |
| Joseph Hernandez 10% owner | Jan 5, 2021 | Sale | −500,000 | $0.58 | $290.00K | 3,523,997 |
| Joseph Hernandez 10% owner | Jan 4, 2021 | Sale | −176,003 | $0.52 | $91.52K | 4,023,997 |
| Robert C. Koski Director | Jan 2, 2021 | Gift | −30,000 | – | – | 212,839 |
| Robert C. Koski Director | Dec 22, 2020 | Sale | −310,000 | $0.43 | $133.30K | 776,483 |
| Joseph Hernandez 10% owner | Dec 2, 2020 | Sale | −5,000,000 | $0.41 | $2.05M | 4,200,000 |
| Fred Telling Director | Nov 24, 2020 | Buy | +100,000 | $0.37 | $37.00K | 439,538 |
| Robert C. Koski Director | Apr 24, 2020 | Gift | −35,000 | – | – | 242,839 |
| Robert C. Koski Director | Dec 30, 2019 | Sale | −100,000 | $0.53 | $53.00K | 1,086,483 |
| Robert C. Koski Director | Dec 27, 2019 | Sale | −100,000 | $0.52 | $52.00K | 1,186,483 |
| Alan Joslyn See Remarks, Director | Mar 25, 2019 | Buy | +66,667 | – | – | 66,667 |
| Fred Telling Director | Mar 25, 2019 | Buy | +100,000 | – | – | 339,538 |
| Thomas L. Koski 10% owner | Sep 18, 2018 | Buy | +22,000 | $0.41 | $9.02K | 277,839 |
| Thomas L. Koski 10% owner | Sep 17, 2018 | Buy | +100,000 | $0.42 | $42.00K | 255,839 |
| Thomas L. Koski 10% owner | Sep 14, 2018 | Buy | +38,860 | $0.42 | $16.32K | 147,649 |
| Thomas L. Koski 10% owner | Sep 14, 2018 | Buy | +2,000 | $0.42 | $840 | 149,649 |
| Thomas L. Koski 10% owner | Sep 14, 2018 | Buy | +100 | $0.41 | $41 | 149,749 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
19.02%
1M shares short
Days to cover
40.1
At 0M shares a day
Change since last report
-0.1%
From 1M shares
Short volume, 20 days
36.6%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Oragenics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 7,233 shares on Sep 25, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Frederick W. Telling Director | Dec 12, 2025 | 210 | $192 | Dec 12, 2025 | Acquired as compensation -- Restricted Stock Units |
| Frederick Telling Director | Dec 6, 2024 | 3,597 | $1.29K | Dec 6, 2024 | Acquired as compensation -- Restricted Stock Units |
| Alan W. Dunton Director | Dec 6, 2024 | 66 | $22 | Dec 6, 2024 | Stock Award |
| Frederick W. Telling Director | Nov 30, 2023 | 3,500 | $12.53K | Nov 30, 2023 | Acquired as compensation -- Restricted Stock Units |
See a number that looks wrong?